Cigna’s New Shared Savings Program Offers $500 if Members Convert to Biosimilars as Billion Dollar Savings Loom

June 29, 2021

Cigna has launched a Shared Savings Program, aimed at reducing costs for its members by identifying alternative drugs offered at a lower price. The program will offer a $500 debit card if members switch to a biosimilar drug, starting with Remicade. The switch could lead to substantial savings; biosimilars could save up to $375 billion by 2031.

“Steve Miller, M.D., chief clinical officer at Cigna, told Fierce Healthcare in an interview that the payer is hoping the program can generate excitement among members about biosimilar drugs, especially as more are coming to market to challenge branded products.” Learn more here.

(Source: Paige Minemyer, Fierce Healthcare, 6/24/21)

Share This Story!